SEC Filings
Praxis Plans Epilepsy Drug Launch With A Proposed Annual List Price Of Up To $600,000
The company also proposed $50,000–$100,000 a year for its essential-tremor drug as both treatments await FDA decisions.
Praxis Precision Medicines (PRAX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The company also proposed $50,000–$100,000 a year for its essential-tremor drug as both treatments await FDA decisions.
Markets
The drug developer has approximately $1.3 billion in cash and investments and is preparing for potential launches while FDA reviews remain pending.
SEC Filings
The relutrigine team is fully hired, with FDA decisions targeted for December and January.